Home › Ignyta Announces RXDX-101 Phase I Data Abstract Accepted for Oral...
 

Keywords :   


Ignyta Announces RXDX-101 Phase I Data Abstract Accepted for Oral...

2014-05-08 02:51:22| Logistics - Topix.net

Phase 1 open label, dose escalation study of RXDX-101, an oral pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.

Tags: data abstract accepted phase

Category:Transportation and Logistics

Latest from this category

All news
»
12.05Weekly Recap: Huggies Launches Skin Essentials Diaper, P&G Recognizes Key Suppliers & More
12.05California Bill Limits Skincare Sales to Teens & Persil Rebrands
12.05Kline Analysts Detail the Medical Dispensing Skin Care Market
12.05Glo30 Starts 2024 Strong with 60% Growth
12.05Zevo On-Body Repellent Teams with American Hiking Society To Provide Bug Bite Defense
12.05L\'Oréals Brand Value Soars to $13.4 Billion
12.05Spate Unveils the Top Sustainability Trends Cycling Google Searches
12.05Oh K! is the Most Searched Beauty Brand in the World: Cosmetify
More »